BioNTech Overhauls Board and Clinches $3.5B Deal as Cancer Pipeline Takes Centre Stage

BioNTech expands board with oncology experts, advances pumitamid with BMS deal, and reports strong balance sheet as it pivots from COVID vaccines to cancer therapies.

The transformation at BioNTech is picking up speed, but the stock remains stuck in neutral. While shareholders handed management a strong vote of confidence at the virtual annual general meeting, approving a bigger board packed with oncology expertise, the share price continues to drift lower — a sign that the market is waiting for hard clinical proof rather than strategic promises.

Board Revamp Signals Cancer Focus

Investors representing 92% of the company’s equity backed all agenda items on Friday. The most impactful decision was expanding the supervisory board from six to eight members. Two new faces join the ranks: Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert, both of whom bring deep experience in late-stage clinical development and commercialisation in oncology.

The message is clear: BioNTech wants oversight that mirrors its future business, not its past as a pure COVID-19 vaccine player. Helmut Jeggle stays on and was elected chairman. Prof. Anja Morawietz and Prof. Rudolf Staudigl also secured renewed mandates.

A $3.5 Billion Anchor Deal

Operationally, the centrepiece of the strategy is pumitamid, a bispecific immunomodulator that chief executive Ugur Sahin has called the company’s flagship programme. A partnership with Bristol Myers Squibb underpins it with an upfront payment of $3.5 billion, with the potential for up to $7.6 billion in milestone payments.

The drug, which has shown activity across several tumour types, will face its first major public test at the end of May when BioNTech presents Phase 2 data at the ASCO conference. The study is a head-to-head comparison against pembrolizumab in lung cancer — a high-stakes showdown that could validate the entire oncology pivot.

Balance Sheet Offers Breathing Room

For the 2025 financial year, BioNTech reported IFRS revenue of €2.87 billion, above its own guidance. But the transition is taking a toll on the top line. First-quarter revenue for 2026 dropped to €118 million from €182 million a year earlier. Full-year guidance sits at €2.0 to €2.3 billion — a range that reflects the ongoing shift from vaccine sales to pipeline investment.

Research and development spending is expected to consume €2.2 billion to €2.5 billion this year, while selling, general and administrative costs are budgeted at €700 million to €800 million. The company’s strong balance sheet cushions this spending: liquid assets and securities stood at roughly €16.8 billion at the end of March.

Restructuring to Cut Costs

BioNTech is also streamlining its manufacturing footprint, planning to consolidate operations by 2029 with annual savings of around €500 million. That involves site closures in Germany and Singapore. The recently integrated CureVac assets are meant to reinforce the late-stage pipeline, which now counts more than 25 Phase 2 and 3 studies.

On the technical side of governance, shareholders approved a new authorised capital framework — the "Genehmigte Kapital 2026" — that can cover up to half of the current share capital, replacing the previous year’s authority. They also greenlit a control and profit transfer agreement for BioNTech Discovery GmbH, enabling tax-efficient offsetting of subsidiary profits against parent company losses. While dry in nature, the move shores up financial flexibility during this expensive R&D phase.

Stock Stays Range-Bound Despite Analyst Optimism

Despite the strategic momentum, the share price closed the session at €76.95, down 2.22%. It sits 11.49% below its 200-day moving average, though it remains 6.14% above its 12-month low. Over the past month the stock has shed roughly 8%.

Wall Street takes a far more bullish view than the chart suggests. Fourteen of 15 analysts tracked by one consensus compile rate the shares a buy, with an average price target of $136.36. A broader survey of 19 analysts shows 15 rating it a "Strong Buy" and four a "Hold", with targets ranging from $94 to $171 — a wide spread that underlines how much hinges on upcoming clinical readouts. Berenberg lowered its target on May 12 but still calls the stock significantly undervalued.

The Next Catalyst

For now, the market’s scepticism is understandable. BioNTech has the cash, the partnerships, and the boardroom expertise to pursue a cancer-focused future. But until the ASCO data or subsequent milestones turn pipeline promise into revenue reality, the equity will remain a bet on binary events rather than a steady growth story. The end of May should offer the first clear answer.